Bafilomycin A1(Baf-A1)

For research use only.

Catalog No.S1413

132 publications

Bafilomycin A1(Baf-A1) Chemical Structure

CAS No. 88899-55-2

Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.

Size Price Stock Quantity  
USD 347 In stock
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Bafilomycin A1(Baf-A1) has been cited by 132 publications

Purity & Quality Control

Choose Selective Proton Pump Inhibitors

Biological Activity

Description Bafilomycin A1 is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis.
Targets
H+-ATPase [1]
(Cell-free assay)
0.44 nM
In vitro

Bafilomycin A1 is a toxic macrolide antibiotic derived from Streptomyces griseus. Bafilomycin A1 inhibits the short circuit current induced by the outer mantle epithelium (OME). The IC50 and maximum inhibition dose of Bafilomycin A1 are 0.17 μM and 0.5 μM, respectively. [2] In addition, Bilomycin A1 inhibits the acid influx with an IC50 value of 0.4 nM. Bafilomycin A1 inhibits the acidification dose-dependently resulting in a lower quenching, and thus a higher fluorescence. [3] Bafilomycin A1 prevents the vacuolization of Hela cells induced by H. pylori, with an inhibitory concentration giving 50% of maximal (ID50) of 4 nM. Bafilomycin A1 is also very efficient in restoring vacuolated cells to a normal appearance. [4] Bafilomycin A1 also affects the transport of endocytosed material from early to late endocytic compartments. Bafilomycin not only dissipates the low endosomal pH but also blocks transport from early to late endosomes in HeLa cells. [5] Bafilomycin A1 at doses of 0.1-1 μM completely inhibits the acidification of lysosomes revealed by the incubation with acridine orange in BNL CL.2 and A431 cells. [6] When Bafilomycin A1 is added to Hanks' balanced salt solution, endogenous protein degradation is strongly inhibited and numerous autophagosomes accumulated in H-4-II-E cells. Bafilomycin A1 also prevents the appearance of endocytosed HRP in autophagic vacuoles. [7]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MCF7 cells MX7GeY5kfGmxbjDhd5NigQ>? NYnKWnhpPCCq MmLwTY5pcWKrdHnvckBw\iC{YYDhcZlkcW5vaX7keYNm\CCjdYTvdIhi\3liaX6gbJVu[W5iTVPGO{Bk\WyuczDlfJBz\XO|aX7nJGVITlBvTFOzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFXHSnAhdGW4ZXzzJIF1KDFyMDDuUUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIILlcIF1cX[nIITvJINwdnS{b3y= NV\JV2xPOjByMkixN|Q>
human HeLa cells NUi0TVlZTnWwY4Tpc44h[XO|YYm= NVP6XoY2PDByIH7N M1n0Nmlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iSHXMZUBk\WyuczDlfJBz\XO|aX7nJGVITlBvTFOzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIFzDN{0zKGyndnXsJIF1KDRyMDDuUS=> M{DWSFE5OzlzOUS5
mouse RAW264.7 cells MWXBdI9xfG:|aYOgZZN{[Xl? M3TuZ|ExOCCwTR?= M3PCSlE3KGh? MmDmTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{Bie3Onc4Pl[EBieyCuYYTlJIFxd3C2b4TpZ{Bk\WyuczDheEAyODBibl2gZYZ1\XJiMU[gbJJ{KHW|aX7nJIFvdmW6aX6gWk1xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJ6KG[ub4egZ5l1d22ndIL5 NITPOVkyQTNyN{O1PS=>
RAW 264.7 cells NWXQfXZ3TnWwY4Tpc44h[XO|YYm= MkXqNVAxKG6P NIK1fXVCdnSrbXnjdo9jcWGuIHHjeIl3cXS7IHHnZYlve3RiU3HscY9v\WyuYTDlcpRmemmlYTDUfZBpcW23cnn1cUAyPDB{ODDpcoZm[3SnZDDpckBTSVdiMk[0Mlch[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4VlKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIlvKGmwZnXjeIVlKGOnbHzzJIF1KDFyMDDuUS=> MV:xPVMxPzN3OR?=
human H4 cells MWLGeY5kfGmxbjDhd5NigQ>? MnLDNE41KM7:TR?= M1XqUVI1KGh? NXnKUYhlUW6mdXP0bY9vKG:oIHzp[4h1KGOqYXnuJFMuT0[SIHzleoVtKGmwIHj1cYFvKEh2IHPlcIx{KGG2IECuOEB2VSCjZoTldkAzPCCqcoOgZpkhcGmpaDD0bJJwfWeqcIX0JIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3C7IILlcIF1cX[nIITvJINwdnS{b3y= M1e0SVE5ODJ2NUi0

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
Ret / EGFR / p75 NGFR; 

PubMed: 21559479     


PC12 cells were treated with various concentrations of bafilomycin A1 for 24 h. Whole cell lysates (40 µg protein) were subjected to SDS–PAGE and immunoblotted with anti-Ret, anti-p75 NGFR, anti-EGFR, and anti-α-tubulin antibodies.

21559479
Growth inhibition assay
Cell viability; 

PubMed: 20534000     


48 h treatment with bafilomycin A1 (BafA1) decreases cell viability at concentrations ≥ 6 nM . *p<0.05 vs. 0 μM vehicle CTL; #p<0.05 vs. 0-3 nM Baf A1.

20534000
Immunofluorescence
AIF; 

PubMed: 25512644     


Confocal microscopic observation of bafilomycin A1-induced AIF subcellular localization. The nucleus was stained with Hoechst 33258 (blue) and AIF by antibody (red). AIF was observed to relocate from cytoplasmic compartments to the nucleus upon bafilomycin A1 treatment. 

LC3; 

PubMed: 24532803     


PANC1 VC and PANC1 N1 cells were preincubated with control medium or this medium containing the late stage autophagy inhibitor bafilomycin A1 (100 nM) for 30 min at 37℃ followed by a 24-h, 37℃Cincubation with either control medium or this medium containing Dp44mT (5 μM) alone, bafilomycin A1 (100 nM) alone, or the combination of Dp44mT (5 μM) and bafilomycin A1 (100 nM).  Immunofluorescence studies with anti-LC3 antibody. Scale, 20 μm.

25512644 24532803
ELISA
TNF-alpha; 

PubMed: 26240140     


BMDMs were incubated with P. falciparumIRBCs in the presence of bafilomycin A1. TNF-α released into culture medium was analyzed by ELISA.

26240140
In vivo Bafilomycin A1 (1 μM and 0.1 μM) completely inhibits the resorptive activity of cultured osteoclasts. [8] Bafilomycin A1 dose-dependently inhibits the rate of Na+ uptake in young tilapia with a Ki of 0.16 μM. [9]

Protocol

Kinase Assay:

[2]
- Collapse

ATPase enzyme activity assays:

The ATPase enzyme assay medium contains 6 mM MgSO4, 50 mM HEPES (pH 7.4), 200 mM Na2SO3 (V-ATPase activator), 0.5 mM sodium ortho-vanadate (P-ATPase inhibitor), 0.5 mM sodium azide (F-ATPase inhibitor) and 3 mM Na2ATP. This medium (1.0 mL), with or without the addition of the V-type ATPase inhibitor bafilomycin A1, is incubated with the filtered homogenate (0.1 mL) for 60 minutes at 23–25 °C. The reaction is stopped by the addition of 1 mL of TCA 3%. Spectrometric blanks are prepared as for the enzyme assay with the exception that the tissue sample is added after the acid. Phosphate analysis is accomplished by adding 2 mL of 1-butanol and 0.2 mL molybdate solution (5 g ammonium molybdate, 22 mL H2SO4 to 100 mL). After vortexing for 15 seconds the solution is neutralised with 0.5 mL citrate solution (100 g/500 mL, pH 7.0) and again vortexed for 15 seconds. The solution is then centrifuged (2000 × g; 3 minutes) to separate the butanol phase and the absorbance of this phase is read at 400 nm. Standards of orthophosphate are prepared (0.1 μM–2.0 μM) and treated in the same way as the enzyme activity assays. Enzyme activity is expressed in μmol of orthophosphate liberated per hour and per milligram of protein. V-ATPase activity is considered to be the difference between the total ATPase activity measured in the presence of Na2SO3, sodium orthovanadate and sodium azide and the ATPase activity measured in the presence of these reagents and of the specific V-ATPases inhibitor Bafilomycin A1.
Cell Research:

[4]
- Collapse
  • Cell lines: HeLa cells
  • Concentrations: ~20 nM
  • Incubation Time: 20 hours
  • Method:

    H. pylori bacteria extract is treated with inhibitors, before addition to HeLa cells, as follows: DCCD 10 mM for 1 hour at 30 ºC; NBD-CI 100 μM for 1 hour at 30 ºC and the reaction is blocked with glycine 10 mM final concentration; NEM 275 μM for 1 hour at 30 ºC and the reaction is blocked by addition of β-mercaptoethanol 275 mM; Mg-ATP 14 μM for 1 hour at 0 ºC; 100 μM KNO3 and 14 μM Mg-ATP for 1 hour at 30 μM; NaCO3 100 μM, pH 11 for 1 hour at 0 ºC. The bacterial extract is then added to cell with a 40-fold dilution at a final concentration of 0.65 mg/mL. Controls are HeLa cells incubated with untreated bacterial extracts and cells treated with inhibitor Bafilomycin A1 under the same conditions as bacterial extracts, at the same concentrations or after a 40-fold dilution. The vacuotating activity of the bacterial extracts is assayed.


    (Only for Reference)
Animal Research:

[9]
- Collapse
  • Animal Models: Young (approximately 9 days old) Mozambique tilapia, Oreochromis mossambicus
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 6 mg/mL (9.63 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 622.83
Formula

C35H58O9
CAS No. 88899-55-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1CC(=CC=CC(C(OC(=O)C(=CC(=CC(C1O)C)C)OC)C(C)C(C(C)C2(CC(C(C(O2)C(C)C)C)O)O)O)OC)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to dissolve it？

  • Answer:

    S1413 Bafilomycin A1(Baf-A1) is soluble in DMSO at 0.1 mg/ml. Please do not use alcohols as solvent, because this compound will degrade in alcohols.

selleck catalog

Proton Pump Signaling Pathway Map

Related Proton Pump Products

  • Elacridar (GF120918) New

    Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor.

  • Verdinexor（KPT-335） New

    Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

  • Lansoprazole

    Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

  • Omeprazole

    Omeprazole is a proton pump inhibitor, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.

  • NEXIUM (esomeprazole magnesium)

    Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion.

  • PF-3716556

    PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease.

  • Zinc Pyrithione

    Zinc pyrithione is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump.

  • Dexlansoprazole

    Dexlansoprazole, the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties.

    Features:A modified release formulation of an enantiomer of lansoprazole.

  • Tenatoprazole

    Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM.

Tags: buy Bafilomycin A1(Baf-A1) | Bafilomycin A1(Baf-A1) supplier | purchase Bafilomycin A1(Baf-A1) | Bafilomycin A1(Baf-A1) cost | Bafilomycin A1(Baf-A1) manufacturer | order Bafilomycin A1(Baf-A1) | Bafilomycin A1(Baf-A1) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID